This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Microarray Patch Business Cases

The MAP Center of Excellence has produced two business case analyses for measles-rubella (MR) vaccine and contraceptive MAPs to inform future investment and development. Please send any feedback or comments on the documents to maps@path.org

Publication date: March 2021

Available materials

    1. Contraceptive MAP Business Case 639.2 KB PDF

      MAPs for the delivery of sustained-release hormonal contraception has emerged as a potential novel technology to address some of the unmet contraception needs in low- and middle-income countries (LMICs) and expand method choice for all women. Several contraceptive MAP designs are in early-stage development. These technologies are intended to be applied briefly to deliver a depot of drug, which would then release continuously and provide contraceptive protection for one to six months. The high unmet need in LMICs suggests a potential market for contraceptive MAPs and an opportunity to expand the contraceptive method mix. There may also be demand for a contraceptive MAP in high-income countries given its convenience and ease of use and the potential to meet the needs of some users. This report describes the potential business case of a hormonal contraceptive MAP. Through the business case analysis, we estimate the potential market opportunity for investment in hormone-based contraceptive MAPs for both LMIC and HIC use, with the intent to inform the commercial viability of advancing hormonal contraceptive MAP development.

    2. MR MAP Business Case 501.7 KB PDF

      The motivation of the MR MAP business case was to evaluate whether MR MAPs represent a sustainable business case for manufacturers to invest. Although the public health value of MR MAPs, in particular their ability to increase vaccine coverage among hard-to-reach populations, the commercial viability is less certain. The MR MAP business case sought to quantify the costs and possible risks of an MR MAP investment and help articulate the potential returns for vaccine manufacturers. Therefore, this business case analysis defines the market opportunity of MR MAPs and evaluate incentives for commercialization partners and global health stakeholders (e.g., donors, procurers) to invest in bringing MR MAPs to licensure for low- and middle-income country use.